Orange Book product · Generic (ANDA)
APREPITANT
APREPITANT
At a glance
Mar 05, 2026
Approved
Generic (ANDA)
Application
Not listed
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Mar 05, 2026
4 mo ago
Today
Pharmaceutical detail
Active ingredient
APREPITANT
Strength
32MG/4.4ML (7.2MG/ML)
Dosage form
EMULSION
Route
INTRAVENOUS
TE code
Not listed
Application
ANDA 218851
Product number
001
Marketing status
DISCN
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of APREPITANT
- 2022APONVIEBrand (NDA)
NDA 216457 · HERON THERAPS INC
- 2017CINVANTIBrand (NDA)
NDA 209296 · HERON THERAPS INC
- 2015EMENDBrand (NDA)
NDA 207865 · MSD MERCK CO
- 2006EMENDBrand (NDA)
NDA 021549 · MSD
- 2020APREPITANTGeneric (ANDA)
ANDA 211835 · TORRENT
- 2017APREPITANTGeneric (ANDA)
ANDA 207777 · GLENMARK SPECLT
- 2012APREPITANTGeneric (ANDA)
ANDA 090999 · SANDOZ
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
